These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 30886955)

  • 1. A phase II trial protocol of Tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial).
    Ramanan AV; Dick AD; Jones AP; Guly C; Hardwick B; Hickey H; Lee R; McKay A; Beresford MW;
    BMC Rheumatol; 2018; 2():4. PubMed ID: 30886955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT.
    Ramanan AV; Dick AD; Jones AP; Hughes DA; McKay A; Rosala-Hallas A; Williamson PR; Hardwick B; Hickey H; Rainford N; Hickey G; Kolamunnage-Dona R; Culeddu G; Plumpton C; Wood E; Compeyrot-Lacassagne S; Woo P; Edelsten C; Beresford MW
    Health Technol Assess; 2019 Apr; 23(15):1-140. PubMed ID: 31033434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial.
    Ramanan AV; Dick AD; Guly C; McKay A; Jones AP; Hardwick B; Lee RWJ; Smyth M; Jaki T; Beresford MW;
    Lancet Rheumatol; 2020 Mar; 2(3):e135-e141. PubMed ID: 32280950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial).
    Ramanan AV; Dick AD; Benton D; Compeyrot-Lacassagne S; Dawoud D; Hardwick B; Hickey H; Hughes D; Jones A; Woo P; Edelsten C; Beresford MW;
    Trials; 2014 Jan; 15():14. PubMed ID: 24405833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT).
    Ramanan AV; Guly CM; Keller SY; Schlichting DE; de Bono S; Liao R; Quartier P
    Trials; 2021 Oct; 22(1):689. PubMed ID: 34627340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for Tocilizumab as a Treatment Option in Refractory Uveitis Associated with Juvenile Idiopathic Arthritis.
    Tappeiner C; Mesquida M; Adán A; Anton J; Ramanan AV; Carreno E; Mackensen F; Kotaniemi K; de Boer JH; Bou R; de Vicuña CG; Heiligenhaus A
    J Rheumatol; 2016 Dec; 43(12):2183-2188. PubMed ID: 27633821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on biologic therapies for juvenile idiopathic arthritis-associated uveitis.
    Thomas J; Kuthyar S; Shantha JG; Angeles-Han ST; Yeh S
    Ann Eye Sci; 2021 Jun; 6():. PubMed ID: 34131629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST-Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): study protocol for a randomised controlled trial.
    Acharya NR; Ebert CD; Kelly NK; Porco TC; Ramanan AV; Arnold BF;
    Trials; 2020 Oct; 21(1):887. PubMed ID: 33109240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Juvenile idiopathic arthritis-associated uveitis.
    Sen ES; Ramanan AV
    Clin Immunol; 2020 Feb; 211():108322. PubMed ID: 31830532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tocilizumab in Juvenile Idiopathic Arthritis Associated Uveitis, a Narrative Review.
    Iannone C; Marelli L; Costi S; Pellico MR; La Franca L; Caporali R; Miserocchi E
    Children (Basel); 2023 Feb; 10(3):. PubMed ID: 36979992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Juvenile idiopathic arthritis-associated uveitis.
    Sen ES; Ramanan AV
    Best Pract Res Clin Rheumatol; 2017 Aug; 31(4):517-534. PubMed ID: 29773271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leflunomide is associated with a higher flare rate compared to methotrexate in the treatment of chronic uveitis in juvenile idiopathic arthritis.
    Bichler J; Benseler SM; Krumrey-Langkammerer M; Haas JP; Hügle B
    Scand J Rheumatol; 2015; 44(4):280-3. PubMed ID: 25993023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tocilizumab for refractory uveitis associated with juvenile idiopathic arthritis: A report of two cases.
    Dipasquale V; Atteritano M; Fresta J; Castagna I; Conti G
    J Clin Pharm Ther; 2019 Jun; 44(3):482-485. PubMed ID: 30815892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Antiinflammatory Treatment on the Onset of Uveitis in Juvenile Idiopathic Arthritis: Longitudinal Analysis From a Nationwide Pediatric Rheumatology Database.
    Tappeiner C; Schenck S; Niewerth M; Heiligenhaus A; Minden K; Klotsche J
    Arthritis Care Res (Hoboken); 2016 Jan; 68(1):46-54. PubMed ID: 26212111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis.
    Ramanan AV; Dick AD; Jones AP; McKay A; Williamson PR; Compeyrot-Lacassagne S; Hardwick B; Hickey H; Hughes D; Woo P; Benton D; Edelsten C; Beresford MW;
    N Engl J Med; 2017 Apr; 376(17):1637-1646. PubMed ID: 28445659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous tocilizumab in the management of non-infectious uveitis in children: a brief report.
    Burlo F; Tumminelli C; Pastore S; Stocco G; Curci D; Lucafò M; Tommasini A; Taddio A
    Pediatr Rheumatol Online J; 2023 Sep; 21(1):99. PubMed ID: 37700264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methotrexate therapy may prevent the onset of uveitis in juvenile idiopathic arthritis.
    Papadopoulou C; Kostik M; Böhm M; Nieto-Gonzalez JC; Gonzalez-Fernandez MI; Pistorio A; Martini A; Ravelli A
    J Pediatr; 2013 Sep; 163(3):879-84. PubMed ID: 23664559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The risk of uveitis in patients with JIA receiving etanercept: the challenges of analysing real-world data.
    Davies R; De Cock D; Kearsley-Fleet L; Southwood T; Baildam E; Beresford MW; Foster HE; Thomson W; Ramanan AV; Hyrich KL;
    Rheumatology (Oxford); 2020 Jun; 59(6):1391-1397. PubMed ID: 31605484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients.
    Calvo-Río V; Santos-Gómez M; Calvo I; González-Fernández MI; López-Montesinos B; Mesquida M; Adán A; Hernández MV; Maíz O; Atanes A; Bravo B; Modesto C; Díaz-Cordovés G; Palmou-Fontana N; Loricera J; González-Vela MC; Demetrio-Pablo R; Hernández JL; González-Gay MA; Blanco R
    Arthritis Rheumatol; 2017 Mar; 69(3):668-675. PubMed ID: 27696756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tocilizumab: The evidence for its place in the treatment of juvenile idiopathic arthritis.
    Herlin T
    Core Evid; 2010 Jun; 4():181-9. PubMed ID: 20694074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.